<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213887</url>
  </required_header>
  <id_info>
    <org_study_id>H14-01095</org_study_id>
    <nct_id>NCT02213887</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications</brief_title>
  <acronym>PK-PPI</acronym>
  <official_title>A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 9-day study is to determine if:&#xD;
&#xD;
        1. Pantoprazole modifies the steady-state plasma concentrations of orally administered&#xD;
           psychotropic medications including valproic acid, lithium, and second-generation&#xD;
           antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine,&#xD;
           paliperidone, quetiapine, risperidone, ziprasidone)&#xD;
&#xD;
        2. Serum gastrin levels change within a week of starting or stopping pantoprazole&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with psychiatric diagnoses may be predisposed to gastroesophageal reflux disease&#xD;
      because of the widespread use of alcohol, cigarettes, and certain psychotropic drugs in this&#xD;
      population. Consequently, they are often prescribed proton pump inhibitors. To our knowledge,&#xD;
      no studies have been conducted to determine the effects of proton pump inhibitors on plasma&#xD;
      levels of psychotropic drugs. The present clinical study will assess the effects of&#xD;
      pantoprazole on the pharmacokinetics of valproic acid, lithium, and second-generation&#xD;
      antipsychotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit participants&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in steady-state plasma concentrations of psychotropic medication(s) at Days 2, 5, and 9.</measure>
    <time_frame>Days 1(baseline), 2 , 5, and 9</time_frame>
    <description>Pharmacokinetic outcome measures often require multiple measurement over time. On Day 1, baseline steady-state plasma concentration of psychotropic medication(s) will be determined. On Days 2, 5, and 9, steady-state plasma concentration of psychotropic medication(s) will be determined and compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting serum gastrin concentrations at Day 9.</measure>
    <time_frame>Days 1 (baseline) and 9</time_frame>
    <description>On Day 1, baseline fasting serum gastrin concentration will be determined. On Day 9, fasting serum gastrin concentration will be determined and compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Psychotic Disorders</condition>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>Start Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.&#xD;
Intervention: Days 2-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stop Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.&#xD;
Intervention: Days 2-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>40 mg PO QAM</description>
    <arm_group_label>Start Pantoprazole</arm_group_label>
    <other_name>Pantoloc</other_name>
    <other_name>Protonix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>0 mg PO QAM</description>
    <arm_group_label>Stop Pantoprazole</arm_group_label>
    <other_name>Pantoloc</other_name>
    <other_name>Protonix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must be fluent in English&#xD;
&#xD;
          -  Participants with a psychiatric diagnosis and currently treated with one or more of&#xD;
             the following medications: valproic acid, lithium, or a second-generation&#xD;
             antipsychotic (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine,&#xD;
             paliperidone, quetiapine, risperidone, or ziprasidone)&#xD;
&#xD;
          -  Participants on a stable dose of valproic acid, lithium, and/or a second-generation&#xD;
             antipsychotic for a sufficient period of time that ensures they are at steady state&#xD;
&#xD;
          -  Participants with symptoms of gastroesophageal reflux disease (GERD) that would&#xD;
             benefit from treatment with pantoprazole or participants currently treated for GERD&#xD;
             with pantoprazole for more than 8 weeks and are currently symptom free.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants that are hypersensitive to pantoprazole&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women of childbearing age not using reliable contraception&#xD;
&#xD;
          -  Any postsurgical complications of the gastrointestinal tract that might impair&#xD;
             absorption&#xD;
&#xD;
          -  Clinically relevant abnormalities of laboratory parameters&#xD;
&#xD;
          -  Participants treated with another acid suppressing agent (e.g., H2 receptor&#xD;
             antagonists, antacids, alginates, etc)&#xD;
&#xD;
          -  Participants treated with atazanavir, delavirdine, erlotinib, nelfinavir, and/or&#xD;
             posaconazole&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ric M. Procyshyn, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alasdair Barr, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Honer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall White, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UBC Hospital - Detwiller Pavilion</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2014</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Ric Procyshyn</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug Interactions</keyword>
  <keyword>Pantoprazole</keyword>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>Psychotropic Drugs</keyword>
  <keyword>Antipsychotic Agents</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Asenapine</keyword>
  <keyword>Clozapine</keyword>
  <keyword>Lurasidone</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>9-hydroxy-risperidone</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Risperidone</keyword>
  <keyword>Ziprasidone</keyword>
  <keyword>Valproic Acid</keyword>
  <keyword>Lithium</keyword>
  <keyword>Gastrins</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Gastroesophageal Reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

